VarmX is focused on developing VMX-C001, a breakthrough universal bypassing agent aimed at restoring blood coagulation in patients taking Factor Xa Direct Oral Anticoagulants (FXa-DOACs), particularly during severe bleeding episodes and emergency surgeries
VarmX is focused on developing VMX-C001, a breakthrough universal bypassing agent aimed at restoring blood coagulation in patients taking Factor Xa Direct Oral Anticoagulants (FXa-DOACs), particularly during severe bleeding episodes and emergency surgeries.